Bicuspid Echocardiac Study Team（BEST）

Prospective Cohort Study on Imaging Genetics of Bicuspid Aortic Valve

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05656820

Acronym

BEST

Enrollment

200

Registered

2022-12-19

Start date

2022-07-01

Completion date

2023-12-31

Last updated

2023-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bicuspid Aortic Valve Disease

Brief summary

The Chinese Bicuspid Aortic Valve (BAV) Ultrasound imaging cohort study is a Chinese BAV ultrasound imaging cohort study. At present, a retrospective study cohort involving more than 30 hospitals has been established. The prospective multi-center study of BAV is expected to include and follow up 200 outpatients and inpatients with BAV. The clinical, ultrasound imaging and treatment parameters of the patients are collected and the patients are followed up for 2 years. To analyze the prognostic characteristics of BAV patients and establish a Chinese BAV database. The primary endpoint was all-cause death, and the secondary endpoints were heart failure, angina, severe aortic stenosis, severe aortic insufficiency, ascending aortic diameter ≥50mm, and surgery (surgical and interventional). According to the different pathological types of aortic valve in different types of BAV, ultrasound imaging was used to evaluate the different forms of valvular leaflet lesions and prognosis. Finally, it provides a basis for the prognosis, treatment method, treatment timing and treatment plan selection of BAV patients, and lays a foundation for the mechanism study of BAV arterial lesions and the establishment of risk model for the prognosis of BAV patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Ultrasound or other imaging tests to diagnose patients with BAV

Exclusion criteria

* Patients with TAV or/and have significant aortic valve calcification * Those deemed unsuitable for enrollment by clinicians (e.g., end-stage patients, mentally ill patients, non-cooperating patients, etc.) * Those who do not agree to be included

Design outcomes

Primary

Measure	Time frame	Description
Diameter of ascending aorta	baseline; once a year; through study completion.	Diameter of ascending aorta shall be taken using leading edge-to-leading edge convention at end diastole.

Countries

China

Contacts

Primary ContactYa Yang

echoyangya99@163.com+86 18911662958

Outcome results